Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hemostatic Disorders × epratuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia 2 Waldenstrom Macroglobulinemia 1 Paraproteinemias 1 Neoplasms 1 Lymphoproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Hemostatic Disorders 1 Hematologic Diseases 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡